Study provides new insight into unknown effects of factors that regulate blood vessel formation
Reviewed by Emily Henderson, B.Sc.Oct 14 2020
A new study by researchers at the University of Eastern Finland provides novel insight into the previously unknown effects of factors regulating blood vessel formation.
In the study,bone morphogenetic factor 6, i.e. BMP6,was shown – for the first time – to regulate blood vessel formation via vascular endothelial growth factor receptor 2 (VEGFR2)and Hippo signaling pathway. The findings can be used in developing treatments for cardiovascular diseases.
Cardiovascular diseases are the leading cause of death in the Western world. In many of these diseases, blood circulation is decreased due to narrowed blood vessels,leading to inadequate tissue perfusion and oxygen deprivation.
The formation of new blood vessels offers a novel treatment option for these diseases.The development of this treatment requires a thorough understanding of cellular signaling mechanisms that regulate neovessel formation.
Bone morphogenetic proteins, BMPs, are growth factors originally discovered as regulators in bone formation. Later on, their regulatory role on the development and maintenance of a wide range of tissues has become apparent.
BMPs have a vital role in the development of the cardiovascular system. In addition,BMPs have been shown to regulate blood vessel formation but their exact mechanisms are unknown.Crosstalkof BMP-signaling with a well-known blood vessel formation regulator, VEGF, and its downstream effectors is poorly understood.
The new study now shows that VEGFgene transfer or oxygen deprivationof thetissueinducethe expression of BMPs. Bone morphogenetic factor 6 ligand was further demonstrated, for the first time, to regulate blood vessel formation.
- Another study finds cross-reactivity T cell responses against SARS-CoV-2
- Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients
- CAR T cell therapy can predict treatment response in patients with large B-cell lymphoma
BMP6 was shown to act in endothelial cells viaVEGFR2and Hippo signaling pathwaysby inducing nuclear localization of Hippo signaling pathway mediator TAZ.Hippo signaling has an important role in tissue size control and cell proliferation, and its malfunction has been associated with cancer.
The findings from this research improve our understanding of multifactorial communication of cell signaling pathways in blood vessel formation. The discoveries related to BMP6 and Hippo signalling can be used in the development of novel treatments for cardiovascular diseases.
The study, openly accessible in Angiogenesis,was carried out in theVascular Biology junior research group ofAcademy Research Fellow, Adjunct Professor Johanna Laakkonenat the A.I. Virtanen Institute for Molecular Sciences.
The main authors of the article, Heidi Pulkkinen, MSc, andMiika Kiema, MSc, are Early Stage Researchers in the Doctoral Programme of Molecular Medicine at UEF. Understanding how the cell types interact in vascular diseases is one of the central research interests of the Laakkonen junior research group. The group's goal is to implement these discoveries for improved treatment and diagnosis of cardiovascular diseases.
The newly published study is supported by the Academy of Finland, the EuropeanResearchCouncil, SigridJuselius Foundation and the Finnish Foundation for Cardiovascular Research.The article is part of a project that has received funding from the European Union's Horizon 2020 research and innovation programme under the MarieSkłodowska-Curie grant agreement.